Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205560 | 0.81 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL5208793 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5349688 | 0.74 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL4575651 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5354135 | 0.72 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5208892 | 0.71 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL5204929 | 0.71 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL5207098 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5207876 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5204562 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | FLT4, KDR, FLT1 | PTGS2 329/4885PTGS1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.